BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22278696)

  • 1. [JAK2 mutation and thrombosis - recommendations for screening].
    Held M
    Dtsch Med Wochenschr; 2012 Feb; 137(5):227. PubMed ID: 22278696
    [No Abstract]   [Full Text] [Related]  

  • 2. [JAK2 mutation and thrombosis - recommendations for screening].
    Linnemann B; Lindhoff-Last E
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
    [No Abstract]   [Full Text] [Related]  

  • 3. Splenomegaly and the JAK2 V617F mutation.
    Langabeer SE
    Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
    [No Abstract]   [Full Text] [Related]  

  • 4. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
    Xavier SG; Gadelha T; Rezende SM; Zalcberg IR; Spector N
    Int J Lab Hematol; 2011 Apr; 33(2):117-24. PubMed ID: 21118380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
    Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
    J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional analysis of atypical mutations in exons 13 and 15 of JAK2 gene in myeloproliferative neoplasms.
    Luo M; Tian T; Zhang Y; Zhang X; Xie J; Xu J; Ren W; Tian C; Wang J; Tan Y; Wang H; Chen X
    Int J Lab Hematol; 2021 Jun; 43(3):e110-e113. PubMed ID: 33244866
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel germline JAK2 mutation in familial myeloproliferative neoplasms.
    Rumi E; Harutyunyan AS; Casetti I; Pietra D; Nivarthi H; Moriggl R; Cleary C; Bagienski K; Astori C; Bellini M; Berg T; Passamonti F; Kralovics R; Cazzola M
    Am J Hematol; 2014 Jan; 89(1):117-8. PubMed ID: 24142793
    [No Abstract]   [Full Text] [Related]  

  • 9. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
    Foucar CE; Stein BL
    JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
    [No Abstract]   [Full Text] [Related]  

  • 10. Absence of the JAK2 V617F mutation in patients with arterial thrombosis without overt myeloproliferative disease.
    Smalberg JH; De Maat MP; Leebeek FW
    J Thromb Haemost; 2008 Sep; 6(9):1606-7. PubMed ID: 18638010
    [No Abstract]   [Full Text] [Related]  

  • 11. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
    Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
    Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
    Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
    Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation.
    McCormick SR; Higgins RR; Grutkoski PS; Bousquet M; Quelen C; Bartholomaus LM; Brousset P
    Br J Haematol; 2015 Apr; 169(2):290-3. PubMed ID: 25316507
    [No Abstract]   [Full Text] [Related]  

  • 15. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
    Zhu P
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
    [No Abstract]   [Full Text] [Related]  

  • 16. JAK2: implications for diagnosis and classification of myeloproliferative disorders.
    Campbell P
    Lijec Vjesn; 2007 May; 129 Suppl 3():30-2. PubMed ID: 18959057
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform.
    Qian J; Lin J; Yao DM; Chen Q; Xiao GF; Ji RB; Li Y; Yang J; Qian Z
    Clin Chim Acta; 2010 Dec; 411(23-24):2097-100. PubMed ID: 20728437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
    Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
    Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
    [No Abstract]   [Full Text] [Related]  

  • 19. Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm.
    Langabeer SE
    J Clin Pathol; 2012 Dec; 65(12):1149-50. PubMed ID: 22872706
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.